IBB · iShares Biotechnology ETF
IBB tracks the Biotechnology and returned +41.5% over the past year.
Key facts
Its ten largest equity positions
| Holding | Weight | |
|---|---|---|
| Vertex Pharmaceuticals, Inc. | 8.09% | |
| Amgen, Inc. | 7.84% | |
| Gilead Sciences, Inc. | 6.85% | |
| Regeneron Pharmaceuticals, Inc. | 4.91% | |
| Argenx SE | 3.76% | |
| Alnylam Pharmaceuticals, Inc. | 3.12% | |
| Natera, Inc. | 2.89% | |
| Revolution Medicines, Inc. | 2.78% | |
| Biogen, Inc. | 2.47% | |
| Illumina, Inc. | 2.07% |
Compare IBB
Also against BINC, BITO, BND, BNDX, BOND, BOXX, BSV, BWET, CGBL, CGDV, CGGR, COWZ, CTA, DBMF, DFUS, DGRO, DGRW, DIA, DVY, DYNF, EDV, EEM, EFA, EMB, EMXC, EWJ, EWT, EWY, EWZ, EZU, FBCG, FDVV, FENI, FLKR, FNDX, FTEC, FXI, GARP, GLD, GLDM, GOVT, GRNY, HDV, HGER, HYG, HYMB, IALT, IAU, IDEV, IEF, IEFA, IEI, IEMG, IGIB, IGM, IGSB, IJH, IJR, IJS, IJT, ILF, INDA, ITOT, IUSB, IVV, IWB, IWC, IWD, IWF, IWM, IWO, IXUS, IYE, IYR, IYW, JAAA, JNK, KRE, LQD, MAGS, MBB, MDY, MGK, MINT, MOAT, MTUM, MUB, NOBL, ONEQ, PDBC, PFF, PULS, PVAL, QQQ, QQQM, QUAL, RDVY, RSP, SCHB, SCHD, SCHF, SCHG, SCHH, SCHP, SCHX, SDY, SGOV, SHV, SHY, SIVR, SLV, SPHD, SPHQ, SPLG, SPMO, SPSB, SPY, SPYD, SPYG, TIP, TLT, URTH, USFR, USHY, USMV, USO, VB, VBIL, VBK, VBR, VCIT, VCLT, VCSH, VDC, VDE, VEA, VEU, VGIT, VGK, VGLT, VGSH, VGT, VHT, VIG, VLUE, VNQ, VO, VOE, VONG, VOO, VOOG, VOX, VPL, VPU, VT, VTEB, VTI, VTIP, VTV, VTWO, VUG, VUSB, VWO, VXF, VXUS, VYM, VYMI, XBI, XHB, XLB, XLC, XLE, XLF, XLG, XLI, XLK, XLP, XLRE, XLU, XLV, XLY, XOP, XOVR, XRT.
Period by period
| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
|---|---|---|---|---|
| 3 months | +18.9% | +3.3% | +15.6 pts | +19.7 pts |
| 6 months | +22.7% | +16.0% | +6.7 pts | +2.0 pts |
| 1 year | +41.5% | +17.5% | +24.0 pts | +18.5 pts |
| 3 years | +60.5% | +77.9% | −17.4 pts | −34.6 pts |
| Since listing | +663.1% | +804.4% | −141.3 pts | −1010.8 pts |
In plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
| What it tracks | Biotechnology |
|---|---|
| Fund type | Index equity fund |
| Expense ratio (485BPOS XBRL, Jul 27, 2026) | 0.44% |
| Price | $202.93 |
| Listed since | Jan 4, 2010 |
| Net assets (SEC filing, whole fund, as filed for Jun 30, 2026) | $9.1bn |
| Below its high (ETFIQ) | −6.5% |
| Holdings | 248 |
| Top ten weight | 44.8% |
| Holdings as of (SEC N-PORT) | Jun 30, 2026 |
| Already in the S&P 500, by weight (ETFIQ) | 35.6% |
| Active share vs the S&P 500 (ETFIQ) | 99.0% |
| Already in the Nasdaq-100, by weight (ETFIQ) | 32.6% |
Questions people ask
- How has IBB performed?
- Over the year to Sep 11, 2026, IBB returned +41.5% with distributions reinvested, against +17.5% for the S&P 500. Over three years the figure is +60.5%.
- What does IBB cost?
- The prospectus expense ratio is 0.44% a year.
- What does IBB hold?
- 248 positions as filed for Jun 30, 2026, with the top ten at 44.8% of the fund. 36% of its weight is in stocks the S&P 500 also holds.
- How far is IBB below its high?
- 6.5% below its high of Aug 19, 2026, measured on the reinvested series to Sep 11, 2026.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Funds near this one
Cite this page. ETFIQ, IBB, core index fund, data as of Sep 11, 2026. https://etfiq.com/funds/IBB Free to use with attribution; the underlying files are at Open data.
ETFIQ covers leveraged and inverse, thematic, buffer, option-income, core index and spot crypto ETFs. This fund is here because the other funds here are measured against it and portfolios hold it. ETFIQ is an independent publisher and makes no recommendations. Standards and sources